CVS Caremark®

| Reference number(s) |
| --- |
| 6832-A |

# Specialty Guideline Management

# Onapgo

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Onapgo | apomorphine hydrochloride |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

Onapgo is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease.

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

### Parkinson’s Disease1,2

Authorization of 6 months may be granted for treatment of motor fluctuations in members with advanced Parkinson’s disease when all of the following criteria are met:

* Member has clearly defined “on” periods.
* The member has “off” periods of at least 3 hours per day despite optimization efforts.
* The member must have had an inadequate response or intolerable adverse event with oral carbidopa/levodopa and one of the following anti-Parkinson agents:
  + Dopamine agonist (e.g., pramipexole, ropinirole)
  + Monoamine oxidase-B (MAO-B) inhibitor (e.g., selegiline, rasagiline)
  + Catechol-O-methyltransferase (COMT) inhibitor (e.g., entacapone, tolcapone)

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for advanced Parkinson’s disease who have demonstrated a positive clinical response with the requested medication.

## References

1. Onapgo [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.; February 2025.
2. National Institute for Health and Care Excellence (NICE) guideline: Parkinson’s disease in adults. Published July 19, 2017. Accessed February 12, 2025. https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061.